• Active, not recruiting

NCT04045795: Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04045795: Phase 1: Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

f isatuximab administered subcutaneously (SC)

NCT04045795: Phase 1: Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

  • To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV)

  • To assess the safety and tolerability (including local injection site tolerability) of isatuximab using the (investigational) isatuximab injector device.

  • To evaluate the pharmacokinetics (PK) of SC and IV isatuximab


Sponsor

Sanofi

 

ClinicalTrials.gov Identifier: NCT05405166

Official Title: A Multi-center, Open-label, Phase 1b Study to Assess the Pharmacokinetics, Safety, and Efficacy of Subcutaneous and Intravenous Isatuximab (SAR650984) in Combination With Pomalidomide and Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

First Posted : August 6, 2019

Click here to see details on ClinicalTrials.gov

 

Isatuximab : National Cancer Institute

Isatuximab : MedlinePlus Drug Information


Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information


Pomalidomide : National Cancer Institute

Pomalidomide : MedlinePlus Drug Information

 

Drug: isatuximab SAR650984 IV

Drug: pomalidomide

Drug: dexamethasone

Drug: isatuximab SAR650984 SC

Device: Investigational injector device

 

Locations

United States, Arizona

United States, California

United States, Ohio

Australia, New South Wales

Australia, Victoria

Europe

Asia

Belgium

France

Japan

Spain


Posts Archive